## **CLAIM AMENDMENTS**

1. (currently amended): A composition for delivery of a biologically active agent to a cell, the composition comprising lipid-based vehicles which comprise conjugates of the formula:

$$A - (BC)$$

wherein:

A is a component [[of]] contained in the structure of said vehicles;

B is a moiety comprising an internalizing peptide;

C is a moiety comprising a biologically active agent;

(BC) is a complex comprising B and C in which B is conjugated to C; and,

A is conjugated to (BC)

- 2. (currently amended): The composition of claim 1, wherein-(BC) is conjugated to a lipid in A A is a lipid component of said vehicles.
- 3. (currently amended): The composition of claim 1-or 2, wherein A is conjugated to (BC) by a coordinate covalent linkage.
- 4. (original): The composition of claim 3, wherein the linkage is between a metal-chelating moiety and a metal-affinity tag, wherein the chelating moiety and affinity tag form a complex with a metal ion.
  - 5. (original): The composition of claim 4, wherein the affinity tag is on (BC).
- 6. (original): The composition of claim 5, wherein the metal-chelating moiety is a metal-chelating lipid in A.
- 7. (currently amended): The composition of any one of claims 4-6 claim 4, wherein the metal-affinity tag has a pKa of about 6 or more.

sd-352922 3

8. (currently amended): The composition of any one of claims 4-7 claim 4, wherein the metal-affinity tag disassociates from the metal-chelating moicty at a pH below normal physiological pH in a mammal.

- 9. (original): The composition of claim 8, wherein the tag begins to disassociate at or below about pH 6.5.
- 10. (currently amended): The composition of any one of claims 4-9 claim 4, wherein the metal-affinity tag is a tract of two or more amino acids having a pKa of about 6 or more.
- 11. (currently amended): The composition of any one of claims 4-10 claim 4, wherein the metal-affinity tag is a his-tag.
- 12. (currently amended): The composition of any one of claims 4-11 claim 4, wherein the metal ion is an ion of a metal selected from the group consisting of copper, nickel, zinc, iron, cobalt, manganese and magnesium.
  - 13. (original): The composition of claim 12, wherein the metal is nickel.
  - 14. (original): The composition of claim 12, wherein the metal is copper.
  - 15. (original): The composition of claim 12, wherein the metal is cobalt.
- 16. (currently amended): The composition of any one of claims 4-15 claim 4, wherein the metal-chelating moiety comprises NTA.
- 17. (currently amended): The composition of claim 1-or 2, wherein A is conjugated to (BC) by a covalent bond.

sd-352922 4

18. (original): The composition of claim 17, wherein the covalent bond is a releasable bond.

- 19. (original): The composition of claim 18, wherein the releasable bond dissociates at a pH below normal physiological pH in a mammal.
- 20. (original): The composition of claim 18, wherein the releasable bond begins to dissociate at or below about pH 6.5.
  - 21. (original): The composition of any one of claims 1-20, wherein A is conjugated to B.
  - 22. (original): The composition of any one of claims 1-20, wherein A is conjugated to C.
- 23. (currently amended): The composition of any one of claims [[1-22]] 1-20, wherein the internalizing peptide of B is derived from Antennapedia.
- 24. (currently amended): The composition of any one of claims [[1-23]] 1-20, wherein the biologically active agent of C is hydrophilic.
- 25. (currently amended): The composition of any one of claims [[1-24]] 1-20, wherein the biologically active agent of C is selected from the group consisting of a peptide, a nucleic acid, and a drug that is not a peptide or nucleic acid.
- 26. (original): The composition of claim 25, wherein C is a peptide and (BC) is a fusion peptide.
  - 27. (original): The composition of claim 26, wherein (BC) is a recombinant peptide.
- 28. (currently amended): A composition according to any one of claims [[1-27]] 1-20, wherein said vehicles comprise a biologically active agent.

sd-352922 5

29. (currently amended): The composition of any one of claims [[1-28]] 1-20, wherein said vehicles are liposomes.

- 30. (currently amended): The composition of any one of claims [[1-29]] 1-20, wherein the biologically active agent of C is an antigen for eliciting an immune response.
- 31. (currently amended): An injectable pharmaceutical preparation comprising a composition according to any one of claims [[1-30]] 1-20, and a pharmaceutically acceptable carrier.

## 32-33. (canceled).

- 34. (currently amended): A method of delivering a biologically active agent to a cell in a patient, comprising administering a composition according to any one of claims [[1-30]] 1-20, to the patient.
  - 35. (original): The method of claim 34, wherein the administering is by injection.

6

sd-352922